Research Progress of Cutaneous Squamous and Basal Cell Carcinomas (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 2138

Special Issue Editors

Department of Head and Neck Surgery, Division of Surgery, MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: nonmelanoma skin cancer; cancer neurobiology; neural regulation of cancer; tumor immunology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Head and Neck Surgery, Division of Surgery, MD Anderson Cancer Center, Houston, TX 77030, USA
Interests: translational research; cancer genomics; squamous cell carcinoma; biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Centre, Houston, TX 77030, USA
Interests: squamous cell carcinoma; thyroid cancer

Special Issue Information

Dear Colleagues,

This Special Issue is the second edition of the Special Issue “Research Progress of Cutaneous Squamous and Basal Cell Carcinomas”, available at https://www.mdpi.com/journal/cancers/special_issues/CSCC_cancers.

We are pleased to invite you to contribute to this Special Issue, which aims to explore the relationship between the TIME (tumor immune microenvironment) and the development, progression, and treatment of cSCC.

More than a million new cases of cutaneous squamous cell carcinoma (cSCC) are diagnosed yearly in the USA, and their incidence is expected to increase worldwide as the population ages. As opposed to other nonmelanoma skin cancers, cSCC is associated with an increased rate of distant metastasis and elevated morbimortality.

Immunosuppression is directly related to the risk of cSCC development, and chronically immunosuppressed individuals, such as organ transplant recipients and those with hematological malignancies, represent a significant portion of cSCC patients. Unfortunately, since immunodeficiency is a major risk factor for metastatic dissemination, these vulnerable patients are more prone to developing advanced disease.

Chronic ultraviolet exposure (UV) is a major etiological factor for cSCC and promotes a unique mutation signature in these tumors. It is also an important immunosuppressive agent and may contribute to a reduction in local immunosurveillance, favoring pro-tumorigenic changes such as skin infection by beta human papillomavirus (HPV), which is considered an important promoter of skin carcinogenesis.

Although the relevance of the tumor immune microenvironment (TIME) in the initiation and progression of cSCC is widely accepted, our understanding of the intricate relationship between the TIME and the cSCC is limited. Consequently, the development and application of new measures for the prevention and treatment of cSCC, especially those linked to immunomodulation, require further exploration.

Original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Moran Amit
Dr. Frederico O. Gleber-Netto
Dr. Neil D. Gross
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor immune microenvironment
  • cutaneous squamous cell carcinoma
  • immunodeficiency
  • biomarkers
  • therapeutics
  • ultraviolet

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

9 pages, 240 KiB  
Review
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation
by Luca Potestio, Massimiliano Scalvenzi, Aimilios Lallas, Fabrizio Martora, Luigi Guerriero, Luigi Fornaro, Laura Marano and Alessia Villani
Cancers 2024, 16(9), 1732; https://doi.org/10.3390/cancers16091732 - 29 Apr 2024
Viewed by 562
Abstract
Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients’ [...] Read more.
Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients’ comorbidities may limit the use of these techniques, making the treatment challenging. As regards BCC, even if hedgehog inhibitors revolutionized the therapeutic scenario, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Different specialists including oncologists, radiologists, dermatologists, and surgeons are required to guarantee an integrated approach, leading to the best management of patients. Moreover, the collaboration among specialists will allow them to best manage the TEAEs, reducing the risk of treatment suspension or discontinuation. Certainly, ongoing studies and more and more emerging real-world evidence, will allow us to better characterize the role of cemiplimab for the management of advanced non-melanoma skin cancer. Full article
10 pages, 1105 KiB  
Review
Neoadjuvant Approaches to Non-Melanoma Skin Cancer
by David C. Wilde, Mica E. Glaun, Michael K. Wong and Neil D. Gross
Cancers 2023, 15(23), 5494; https://doi.org/10.3390/cancers15235494 - 21 Nov 2023
Cited by 1 | Viewed by 1212
Abstract
Surgery and external-beam radiation therapy are the primary treatment modalities for locally advanced NMSC, but they can lead to impairment of function and disfigurement in sensitive areas such as the head and neck. With the advent of targeted systemic therapies and immunotherapy, physicians [...] Read more.
Surgery and external-beam radiation therapy are the primary treatment modalities for locally advanced NMSC, but they can lead to impairment of function and disfigurement in sensitive areas such as the head and neck. With the advent of targeted systemic therapies and immunotherapy, physicians have explored the ability to offer neoadjuvant therapy for NMSC in order to reduce surgically induced morbidity. Provided herein is a guide to current applications of neoadjuvant systemic therapies for NMSC and future directions. Full article
Show Figures

Figure 1

Back to TopTop